Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients (RADAR)

This study has been completed.
Merck Sharp & Dohme Corp.
Tibotec Pharmaceutical Limited
Information provided by (Responsible Party):
Roger Bedimo, M.D., Dallas VA Medical Center Identifier:
First received: May 8, 2008
Last updated: September 5, 2014
Last verified: September 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2012
  Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):